# Call for Late-Breaker Abstracts
## 20th Annual Conference on Vaccine Research (ACVR 2017)
## April 24-26, 2017
## Bethesda, MD

The National Foundation for Infectious Diseases (NFID) invites late-breaker abstract **poster submissions of original research that contains data unavailable by the original December 2016 deadline** in the areas of: adjuvants; epidemiology and burden of disease; new and emerging vaccines; preclinical and clinical trials; vaccine production and delivery; and vaccine safety.

Late-breaker abstracts will undergo formal peer-review evaluation for quality of research, educational or scientific content, and overall impact. Late-breaker abstracts are highly competitive; only abstracts containing new, novel, cutting-edge information will be considered. Abstracts accepted will be presented as posters only.

## How to Submit:

All late-breaker abstracts must be submitted electronically through the ACVR online submission site (http://bit.ly/2017ACVRabstracts). All users will be required to create an account. You may begin the submission process and return to your saved proposal any time prior to the submission deadline. Abstracts submitted by email, fax, or mail will not be accepted. Research findings that were available prior to the original December 2016 abstract deadline are not considered to be late-breaking and will not be accepted.

## Schedule:

| | |
|---|---|
| January 2017 | Call for late-breaker abstracts submission site opens |
| March 2017 | Late-breaker abstract submission deadline (11:59 PM PT). No extensions will be granted. |
| March 2017 | Acceptance/Rejection notifications issued for all submitted abstracts |
| April 24-26, 2017 | 20th Annual Conference on Vaccine Research |
| | Bethesda North Marriott Hotel & Conference Center, Bethesda, MD |

## Categories for Abstract Submission:

The submitting author must select the most appropriate subject category from the list below. The ACVR Planning Committee reserves the right to modify the category selected to more appropriately reflect the abstract content.

- Adjuvants
- Epidemiology and Burden of Disease
- New and Emerging Vaccines
- Preclinical and Clinical Trials
- Vaccine Production and Delivery
- Vaccine Safety

## Abstract Format:

All abstracts must be submitted in English and must reflect original work. The research may have been published or presented at another scientific meeting and include updated information based on new data generated and/or analyzed following the December 2016 original submission deadline. Multiple submissions of the same abstract

will automatically be rejected.

Abstracts must contain the following components:

- **Abstract Title:** *(75 word limit)*
  - Use a concise title that summarizes the content
  - Capitalize the first letter of each word, except for prepositions, articles, and species names
  - Italicize all specific names of microorganisms and scientific organism names
  - **DO NOT** use any of the following formats for the abstract title
    - **Bold**
    - all lower case
    - ALL UPPER CASE
    - *All Italics*
    - "Quotes around your abstract title"
- **Background:** *(150 word limit)* a concise statement of the issue under investigation or a hypothesis
- **Methods:** *(200 word limit)* the experimental methods used (including the statistical analyses employed)
- **Results & Conclusions:** *(270 word limit)* a summary of specific findings and results (statistical analyses used to support the conclusions should be included; concluding statements such as "the results will be discussed" or "to be completed" are not acceptable)
- **Author(s):** *(limit of 15 authors)* The abstract submitter should note the First Author, Presenting Author (individual who will be presenting the research at the conference if accepted), and any co-authors of the work. Note that the full contact information and CVs will be requested for all authors. The system allows you to send an email to each of the authors for them to complete this information directly.
- **Disclosures:** NFID requires all presenters and reviewers to disclose all relevant financial relationships with any commercial interest in any amount, occurring within the past 12 months that could create a conflict of interest. Disclosure information is reviewed in advance to manage and resolve any real or perceived conflict of interest that may affect the balance and scientific integrity of an educational presentation.
- **Learning Objective(s):** You are **required** to submit at least one learning objective. Sample learning objectives are available at: www.nfid.org/professional-education/presenter-resources.
- **References:** You are **required** to submit at least one literature reference/citation to support your research/data (two are preferred.) Use the conventional style for listing references as referred by the American Medical Association (AMA) Manual of Style: A Guide for Authors and Editors. Sample references are available at: http://jama.jamanetwork.com/public/instructionsForAuthors.aspx#References.

## Selection:

All abstract submissions will be reviewed for scientific merit and relevance to the field of vaccine research by members of the ACVR Planning Committee. Abstract submissions are reviewed for the following: a clearly stated hypothesis or issue; experimental and statistical methods used; specific findings (statements such as "the data will be presented," are unacceptable); and specific conclusions (statements such as "the results will be discussed," are unacceptable). Authors of accepted abstracts will be invited to present their work as a poster presentation.

## Registration & Attendance:

**All accepted abstract presenters must register for the conference and pay the appropriate registration fee by no later than March 31, 2017 or their abstract will be withdrawn from the program.** Presenters who fail to appear at the conference at the specified time(s) will forfeit their registration fee and any future abstract submissions will be automatically disqualified from consideration for two years. No support for travel costs or registration fees is available.

## Abstract Publication:

All abstracts will be published in the onsite program book. Select presentations may be included in future publications with author permission.